Wexford Capital LP Has $873,000 Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Wexford Capital LP decreased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 11.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 398,463 shares of the company’s stock after selling 50,583 shares during the quarter. Wexford Capital LP owned about 0.56% of Ventyx Biosciences worth $873,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in VTYX. Barclays PLC grew its position in shares of Ventyx Biosciences by 273.1% in the third quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after purchasing an additional 58,776 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Ventyx Biosciences by 2.0% in the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock valued at $2,196,000 after purchasing an additional 20,236 shares during the last quarter. Catalina Capital Group LLC acquired a new position in shares of Ventyx Biosciences in the fourth quarter valued at approximately $25,000. Rhumbline Advisers grew its position in Ventyx Biosciences by 44.4% during the fourth quarter. Rhumbline Advisers now owns 132,825 shares of the company’s stock worth $291,000 after buying an additional 40,813 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its position in Ventyx Biosciences by 97.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock worth $52,000 after buying an additional 11,792 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $1.40 on Monday. The company has a market capitalization of $99.63 million, a P/E ratio of -0.59 and a beta of 0.73. Ventyx Biosciences, Inc. has a 1 year low of $0.78 and a 1 year high of $5.66. The business’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $1.76.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. On average, sell-side analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.